N
Nykode Therapeutics
Clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies
At a glance
- Status
- Listed
- Founded
- 2007
- Headquarters
- Oslo, Norway
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- SMSarsia Seed Management
Series B and later5 investors entered at this stage
- INInven2
- UOUniversity of Oslo
- RNResearch Council of Norway
- KRKreftforeningen
- OHOslo University Hospital
Ownership
Share of equity by holder, from Dealroom's shareholder data. Stakes as last recorded by Dealroom (May/2026).
“Other / undisclosed” is the 46.2% not attributed to a named shareholder. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
5 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nykode Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nykode Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.